Zhiyuan Lu

Dr. Zhiyuan Lu

Department of Oral and Maxillofacial Surgery, Stomatology Medical Center, Guangzhou Women and Children’s Medical Center

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2018 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
YLYanzhu Lin
Yanzhu Lin
KCKai Chen
Kai Chen
ZLZhiyuan Lu
Zhiyuan Lu
LZLei Zhao
Lei Zhao
YTYalan Tao
Yalan Tao
XCXin-ping Cao
Xin-ping Cao
To compare the efficacies and toxicities of intensity-modulated radiotherapy (IMRT) with three-dimensional conformal radiotherapy (3D-CRT) or conventional two-dimensional radiotherapy (2D-RT) for definitive treatment of cervical cancer. A meta-analysis was performed using search engines, including PubMed, Cochrane Library, Web of Science, and Elsevier. In the meta-analysis, odds ratios (ORs) were compared for overall survival (OS), disease-free survival (DFS), and acute and chronic toxicities. Included data were analysed using RevMan 5.2 software. Six studies encompassing a total of 1008 patients who received definitive treatment (IMRT = 350, 3-DCRT/2D-RT = 658) were included in the analysis. A comparison of 3-year OS and 3-year DFS revealed no significant differences between IMRT and 3D-CRT or 2D-RT (3-year OS: OR = 2.41, 95% confidence interval [CI]: 0.62–9.39, p = 0.21; 3-year DFS: OR = 1.44, 95% CI: 0.69–3.01, p = 0.33). The incidence of acute gastrointestinal (GI) toxicity and genitourinary (GU) toxicity in patients who received IMRT was significantly lower than that in the control group (GI: Grade 2: OR = 0.5, 95% CI: 0.28–0.89, p = 0.02; Grade 3 or higher: OR = 0.55, 95% CI: 0.32–0.95, p = 0.03; GU: Grade 2: OR = 0.41, 95% CI: 0.2–0.84; p = 0.01; Grade 3 or higher: OR = 0.31, 95% CI: 0.14–0.67, p = 0.003). Moreover, the IMRT patients experienced fewer incidences of chronic GU toxicity than did the control group (Grade 3: OR = 0.09, 95% CI: 0.01–0.67, p = 0.02). IMRT and conventional radiotherapy demonstrated equivalent efficacy in terms of 3-year OS and DFS. Additionally, IMRT significantly reduced acute GI and GU toxicities as well as chronic GU toxicity in patients with cervical cancer.

14 May 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
YLYanzhu Lin
Yanzhu Lin
HZHui Zhai
Hui Zhai
YOYi Ouyang
Yi Ouyang
ZLZhiyuan Lu
Zhiyuan Lu
CCChengbiao Chu
Chengbiao Chu
XCXin-ping Cao
Xin-ping Cao
Pyruvate kinase isozyme type M2 (PKM2) catalyzes the final step in glycolysis and has been found to be up-regulated in multiple human malignancies. However, whether PKM2 regulates the radiosensitivity of human cervical cancer (CC) remains unknown. The expression of PKM2 in 94 patients with CC in the complete response (CR) and noncomplete response (nCR) groups, was evaluated by immunohistochemistry. The effect of PKM2 inhibition on radiosensitivity, the cell cycle, DNA damage, and apoptosis was evaluated by immunofluorescence analysis, colony formation assay, flow cytometry analysis and Western blotting. PKM2 expression was more highly expressed in the nCR group than that in CR group and PKM2 expression was enhanced in CC cells after ionizing radiation (IR). In addition, knockdown of PKM2 combined with IR significantly reduced cell growth, promoted apoptosis, and enhanced radiosensitivity. Additionally, knockdown of PKM2 with IR resulted in increased phosphorylation of DNA repair checkpoint proteins (ATM) and phosphorylated-H2AX. Moreover, knockdown of PKM2 combined with IR significantly increased the expression of cleaved caspase 3 and caspase 9, whereas Bcl2 expression was suppressed. Furthermore, knockdown of PKM2 combined with IR markedly reduced the expression of several cancer stem cell biomarkers in vitro, including NANOG, OCT4, SOX2, and Bmi1. The results of our study suggests that PKM2 might be involved in mediating CC radiosensitivity and is identified as a potentially important target to enhance radiosensitivity in patients with CC.

16 May 2022 in Aging
Verified
Journal Article
Open access
PDF file
YCYiyang Chen
Yiyang Chen
ZLZeyu Li
Zeyu Li
JLJianfeng Liang
Jianfeng Liang
JLJiayu Liu
Jiayu Liu
JHJiansuo Hao
Jiansuo Hao
ZLZhiyuan Lu
Zhiyuan Lu
Introduction: CircRNAs are engaged in the tumorigenesis and progression of oral squamous cancer cells (OSCC). However, the function and underlying mechanism of circRNAs on tumor-associated immunity escape are largely unknown. Materials and methods: We analyzed the expression pattern of has_circ_0069313 in our in-house database and its correlation with OSCC prognosis. Immunohistochemistry was applied to detected PDL1 expression. RNA fluorescence in situ hybridization was applied to detect subcellular location of circRNA. A luciferase activity assay was used to detect the interaction of has_circ_0069313 and miR-325-3p and its downstream target, Foxp3. Exosomes were collected to detect the exosomal circRNAs and co-culture assays were performed to detect the function of exosomal circRNAs on Tregs. Results: has_circ_0069313 was upregulated in OSCC tissues and predicts poor prognosis. has_circ_0069313 promotes immunity escape through inhibiting miR-325-3p-induced Foxp3 degradation. has_circ_0069313 is an exosomal circRNA and the transfer of has_circ_0069313 to Treg cells promotes the Treg function through maintaining Foxp3 levels. Conclusion: Our results indicate that has_circ_0069313 induces OSCC immunity escape via the miR-325-3p-Foxp3 axis in both OSCC cells and Treg cells.

28 October 2020 in Cancer Biomarkers
Verified
Journal Article
Closed access
QWQuan Wan
Quan Wan
WYWangxiang Yan
Wangxiang Yan
YLYonghong Liu
Yonghong Liu
YLYanzhu Lin
Yanzhu Lin
ZLZhiyuan Lu
Zhiyuan Lu
OBJECTIVE: In this study, we determined the prognostic values of magnetic resonance imaging (MRI)-based primary tumor regression and serum squamous cell carcinoma antigen (SSCC-Ag) levels 4 weeks after definitive radiotherapy (RT) in cervical squamous cell carcinoma (CSCC) patients. METHODS: This was a retrospective study involving 218 patients with histologically confirmed CSCC (stages IB-IVA). All the patients received definitive RT. Pre- and post-RT pelvic MRI and SSCC-Ag levels were measured. Locoregional control (LRC), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) were evaluated, and possible OS prognostic factors were analyzed. RESULTS: The median follow-up time was 25.57 (1.73–58.93) months. Thirty-six and 68 patients died and experienced recurrence, respectively, and the primary tumors of 130 (59.6%) and 88 (40.4%) patients exhibited complete response (CR) and non-CR, respectively. The 3-year OS, DFS, LRC, and DMFS rates were significantly higher in the CR than in the non-CR patients (85.2% vs. 67.9%, 78.9% vs. 39.0%, 93.4% vs. 63.8%, and 83.4% vs. 54.5%, respectively; p< 0.05). The 3-year OS, DFS, LRC, and DMFS rates were significantly lower in the patients with high post-RT SSCC-Ag levels than in those with low post-RT SSCC-Ag levels (38.0% vs. 83.9%, 21.2% vs. 66.3%, 73.0% vs. 84.9%, and 26.5% vs. 79.0%, respectively; p<0.05). Multivariate analyses indicated that SSCC-Ag levels were an independent OS predictor (HR: 5.749, 95% CI: 2.598–12.723, p< 0.001). CONCLUSION: Post-RT SSCC-Ag levels are OS independent prognostic factors in CSCC patients receiving RT. Timely and optimized treatment plans for CSCC patients after 4 weeks of RT are necessary when patients with persistent tumor and/or positive SSCC-Ag.

1 January 2022
Verified
Journal Article
Closed access
JHJiansuo Had
Jiansuo Had
QWQuan Wan
Quan Wan
JLJiayu Liu
Jiayu Liu
WWWenli Wu
Wenli Wu
JLJiameng Liu
Jiameng Liu
ZLZhiyuan Lu
Zhiyuan Lu

17 March 2026 in International Dental Journal
Verified
Journal Article
Open access
YLYanzhu Lin
Yanzhu Lin
LZLuodan Zhao
Luodan Zhao
YHYing Huang
Ying Huang
YCYuee Chen
Yuee Chen
QWQuan Wan
Quan Wan
XZXiangsong Zhang
Xiangsong Zhang
Oral squamous cell carcinoma (OSCC) is a common oral cavity malignancy with a poor prognosis. Although chemokine-like receptor 1 (CMKLR1) has been implicated in tumor progression in several types of cancer, its role and underlying mechanisms in OSCC remain unclear. In this study, we examined the role and mitochondrial metabolism pattern of CMKLR1 in OSCC progression. CMKLR1 expression was evaluated using data obtained from The Cancer Genome Atlas database and from immunohistochemical, RT-qPCR, and Western blotting analyses involving OSCC tissues and cell lines. Functional assays focusing on proliferation, migration, invasion, and colony formation were conducted after CMKLR1 knockdown or overexpression in OSCC cells. Proteomic analyses were conducted to identify CMKLR1-associated signaling pathways. Seahorse assays were used to assess mitochondrial oxidative phosphorylation (OXPHOS). In addition, the effect of mitochondrial inhibition with IACS-010759 was evaluated in CMKLR1-overexpressing models. Finally, signaling dependency was tested through PI3K/AKT inhibition and PGC-1α depletion. CMKLR1 expression was significantly elevated in OSCC, correlating with advanced OSCC, lymph node metastasis, and poor prognosis. CMKLR1 knockdown inhibited cell proliferation, migration, invasion, and epithelial-to-mesenchymal transition in vitro and suppressed tumor growth in vivo, whereas CMKLR1 overexpression had the opposite effect. Proteomic profiling and metabolic assays revealed that CMKLR1 knockdown suppressed mitochondrial function, decreased OXPHOS activity, and reduced ATP production. Additionally, pharmacological inhibition of OXPHOS with IACS-010759 significantly abrogated the tumor-promoting effects driven by CMKLR1 overexpression, thereby supporting a CMKLR1-OXPHOS regulatory axis in OSCC. Mechanistically, CMKLR1 activated PI3K/AKT signaling and induced PGC-1α production. Pharmacological blockade of PI3K/AKT abrogated CMKLR1-dependent PGC-1α upregulation, and PGC-1α depletion attenuated CMKLR1-driven mitochondrial respiration. CMKLR1 is a novel driver of OXPHOS in OSCC that functions through the PI3K/AKT/PGC-1α axis. Targeting mitochondrial metabolism may represent a promising therapeutic strategy for patients with overexpression of CMKLR1 and OSCC.